Fresh analysis suggests that people who stop using new slimming jabs like semaglutide or tirzepatide tend to recover shed pounds at a significantly accelerated pace than those who halt traditional lifestyle programs.
Published data in a major health publication shows that while overweight individuals can lose substantial amounts of their total mass while undergoing treatment, the weight comes back at an estimated rate of nearly a kilo each month after stopping.
"Users using such medications need to be informed of the danger of rapid rebound weight gain when the treatment ends," cautioned researcher Dr. Susan Jebb.
Such speed of recovery means a return to starting mass in about 18 months.
Analyzing Therapies
The research, which looked at dozens of trials involving thousands of participants, contrasted the results of the injectable medications with conventional dieting.
The team note that individuals who shed pounds through diet and exercise generally experience a slower weight regain—perhaps 0.1 kg a month—after stopping.
Understanding the Rapid Rebound
Doctors propose the mode of action of the injections accounts for the accelerated weight return.
The injections imitate a natural hormone called glucagon-like peptide-1, which moderates appetite.
"Artificially providing the hormone levels several times higher than normal could lead to the body to generate a reduced amount of its own natural GLP-1, and could lessen responsiveness to its actions," explained Dr. Adam Collins, a dietetics expert.
"Discontinuation of this GLP-1 'fix' leads to hunger is uncontrolled, making binge eating a significant risk."
A Chronic Condition?
The NHS advise the jabs for individuals with obesity-related health risks, accompanied by recommended lifestyle changes.
Professionals contend that, due to the high risk of relapse, the therapy might need to be long-term.
This view is supported by pharmaceutical companies, who note that the results "emphasize the persistent character of obesity," similar to managing conditions like hypertension.
Patient Experiences
Users who have stopped the medication report a powerful resurgence of appetite.
"It was like something flipping and you become extremely hungry," described an individual.
This challenge is compounded if patients have not established lasting lifestyle or habit modifications during treatment.
Significant Adoption
Survey data show that millions of people in the UK have tried these injections in the last 12 months, with interest being substantial.
- Use is greater among females than men.
- The middle-aged demographic shows the greatest usage rates.
- A large proportion access the medications through private healthcare rather than public health services.
In conclusion, experts caution that while GLP-1 drugs are potent agents for shedding pounds, they are not a standalone solution and long-term success hinges on integrated lifestyle support.
